Losarta 50

/ CTS

Hypertension in adults: Starting dosage is usually 50 mg per day. The maximal antihypertensive effect is obtained 3-6 weeks after starting treatment.
Hypertension with type II diabetes in adults: The starting dosage is usually 50 mg per day.
Heart failure in adults: The starting dosage is usually 12.5 mg in one dose per day. Increase the daily dosage gradually until reaching the desirable maximal effect, as determined by the doctor.

Treatment of hypertension.
Treatment of heart failure, usually in addition to diuretics and/or digitalis if use of an ACE inhibitor is not appropriate.
Switching patients with heart failure who are stable on an ACE inhibitor to Losartan is not recommended.
Renal protection in Type 2 diabetic patients with proteinuria: Losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria.
Reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy.
This medicinal product is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy.
The benefit of Losartan on the primary composite end point was largely driven by reduction in the risk of stroke.

Known hypersensitivity to any component of the product. Pregnancy. lactation.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Although there is no experience with the use in pregnant women, animal studies have demonstrated fetal and neonatal injury and death, the mechanism of which is believed to be pharmacologically mediated through effects on the renin-angiotensin system. In humans, fetal renal perfusion, which is dependent upon the development of the renin-angiotensin system, begins in the second trimester, thus, risk to the fetus increases if treatment is administered during the second or third trimesters of pregnancy. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death in the developing fetus. When pregnancy is detected, treatment should be discontinued as soon as possible.

Please refer to the license holder for further details.